Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the immunisation protects at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by activating the mother’s body’s defences to produce defence proteins, which are then transferred to the foetus through the placenta. This mother-derived protection offers newborns with instant defence from the point of delivery, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence indicating that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85 per cent protection when immunised 4 weeks before birth
• Maternal antibodies transferred through the placenta safeguard newborns from day one
• Coverage achievable with two-week gap before premature birth
• Vaccination during the third trimester still provides significant infant protection

Compelling evidence from current research

The efficacy of the pregnancy RSV vaccine has been established through a extensive research programme conducted across England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month timeframe, providing strong and reliable data of the vaccine’s practical effectiveness. The study’s results have been endorsed by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scope of this study provides healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.

The results paint a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This marked difference underscores the vaccine’s critical role in reducing the risk of serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.

Methodology and scope of study

The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospitalisations. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or small subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology measured actual clinical results rather than controlled laboratory conditions, providing real-world data of how the vaccine functions when administered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.

Comprehending RSV and the threats

Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.

The infection produces deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to breathe and feed adequately. Parents often witness their babies struggling visibly, their chests rising whilst they work to get adequate oxygen into their weakened respiratory system. Whilst most infants recover with palliative treatment, a small but significant group succumb from RSV complications yearly, making immunisation programmes a essential public health imperative for defending the most vulnerable and youngest members of society.

• RSV causes lung inflammation, resulting in severe breathing difficulties in infants
• Approximately half of newborns acquire the infection during their first few months alive
• Symptoms span from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
• Over 20,000 UK infants require serious hospital care for RSV annually
• Few infants succumb to RSV complications annually in the UK

Uptake rates and professional guidance

Since the RSV vaccine programme launched in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing is crucial for guaranteeing newborns receive the maximum immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies passed to their babies through the placenta.

The messaging from health authorities stays clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.

Regional disparities in vaccine uptake

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These geographical variations reflect variations in healthcare infrastructure, engagement approaches, and community involvement initiatives, though the national data demonstrates robust and reliable protection regardless of geographical location.

• NHS trusts launching diverse outreach initiatives to connect with expectant mothers
• Inconsistencies across regions in immunisation take-up across England require targeted improvement
• Regional health providers modifying schemes to align with specific population needs

Practical implications and parental perspectives

The vaccine’s impressive effectiveness provides real advantages for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the introduction of this safeguarding intervention, the 80% reduction in admissions means thousands of infants shielded from serious illness. Parents no more face the distressing scenario of watching their newborns struggle for breath or labour to feed, symptoms that mark severe RSV infections. The vaccine has markedly changed the terrain of neonatal breathing health, providing expectant mothers a preventative option to shield their youngest infants during those vital initial period.

For families like that of Malachi, whose acute RSV infection resulted in severe brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s support of the jab underscores the transformative consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to women in pregnancy in their late pregnancy, converting what was once an inevitable seasonal threat into a manageable risk.